Treatment of isolated systolic hypertension in the elderly

References

• Lloyd-Jones DM, Leip EP, Larson MG, Vasan RS, Levy D. Novel approach to examining first cardiovascular events after hypertension onset. Hypertension 45(1), 39–45 (2005).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Pepe S, Lakatta EG. Aging hearts and vessels: masters of adaptation and survival. Cardiovasc. Res. 66(2), 190–193 (2005).
   PubMedGoogle Scholar
• Duprez DA. Role of the renin–angiotensin–aldosterone system in vascular remodeling and inflammation: a clinical review. J. Hypertens. 24(6), 983–991 (2006).
   PubMed Web of Science ®Google Scholar
• White WB, Wolfson L, Wakefield DB et al. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. Circulation 124(21), 2312–2319 (2011).
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ et al.; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 123(21), 2434–2506 (2011).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25(9), 1751–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Cabrera J, Cheng JQ et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 306(23), 2588–2593 (2011).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279, 1903–1907 (1998).
   PubMed Web of Science ®Google Scholar
• Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat. Rev. Cardiol. 8, 13–28 (2011).
   PubMed Web of Science ®Google Scholar
• Palatini P, Thijs L, Staessen JA et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch. Intern. Med. 162, 2313–2321 (2002).
   PubMed Web of Science ®Google Scholar
• Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil SR/Trandolapril study (INVEST). Eur. Heart J. 29, 1327–1334 (2008).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350(9080), 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch. Intern. Med. 160(2), 211–220 (2000).
   PubMedGoogle Scholar
• SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327(10), 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 355, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362(9386), 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Remme WJ, Deckers JW, Fox KM, Ferrari R, Bertrand M, Simoons ML; EUROPA Investigators. Secondary prevention of coronary disease with ACE inhibition – does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc. Drugs Ther. 23(2), 161–170 (2009).
   PubMedGoogle Scholar
• Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study. Atherosclerosis 204(1), 273–275 (2009).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlöf B et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Turgut F, Balogun RA, Abdel-Rahman EM. Renin–angiotensin–aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. Clin. J. Am. Soc. Nephrol. 5(7), 1330–1339 (2010).
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386), 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386), 777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D et al.; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol. 44(6), 1175–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Weintraub HS, Duprez DA, Cushman WC et al. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. Cardiovasc. Drugs Ther. 26(2), 145–155 (2012).
   PubMedGoogle Scholar
• Pinto R, Gradman AH. Direct renin inhibition: an update. Curr. Hypertens. Rep. 11(6), 456–462 (2009).
   PubMedGoogle Scholar
• Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J. Hum. Hypertens. 24(9), 600–608 (2010).
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ. Cardiorenal endpoints in a trial of aliskiren Type 2 diabetes. N. Engl. J. Med. doi: 10.1056/NEJMoa1208799 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 358(18), 1887–1898 (2008).
   PubMed Web of Science ®Google Scholar
• Peters R, Beckett N, Forette F et al.; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7(8), 683–689 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenthal T, Nussinovitch N. Managing hypertension in the elderly in light of the changes during aging. Blood Press. 17(4), 186–194 (2008).
   PubMed Web of Science ®Google Scholar
• Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr. Pharm. Des. 10(29), 3615–3620 (2004).
   PubMedGoogle Scholar
• Hirsch AT, Duprez D. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. Vasc. Med. 8(4), 273–278 (2003).
   PubMedGoogle Scholar
• ACCORD Study Group; Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
   PubMed Web of Science ®Google Scholar
• Duprez DA, Jacobs DR Jr, Lutsey PL et al. Association of small artery elasticity with incident cardiovascular disease in older adults: the multi-ethnic study of atherosclerosis. Am. J. Epidemiol. 174(5), 528–536 (2011).
   PubMed Web of Science ®Google Scholar
• Peralta CA, Jacobs DR Jr, Katz R et al. Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR >60 ml/min/1.73 m2: the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Kidney Dis. 59(1), 41–49 (2012).
   PubMed Web of Science ®Google Scholar
• Peralta CA, Adeney KL, Shlipak MG et al. Structural and functional vascular alterations and incident hypertension in normotensive adults: the Multi-Ethnic Study of Atherosclerosis. Am. J. Epidemiol. 171(1), 63–71 (2010).
   PubMedGoogle Scholar